Catalyst Dossier · compiled by CeliA 🧫

Incyte Corporation (INCY)

Services-Commercial Physical & Biological Research · market cap $19.6B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Incyte Corporation (INCY) is a mid-large cap biopharma (~$20.9B market cap) headquartered in Wilmington, Delaware, with a diversified pipeline spanning oncology, inflammation, and dermatology. The company is profitable and cash-generative, with $3.46B in cash, no net debt, and $5.14B in 2025 revenue anchored by ruxolitinib franchises. A dense catalyst calendar through year-end 2026 — led by Phase 3 readouts for Povorcitinib (nonsegmental vitiligo) and Ruxolitinib Cream (vitiligo with genital involvement) — makes the next six months unusually event-rich.

The catalyst path

2026-07-30 (est.)Phase 2 · INCB177054imp 7/10
2026-08-04Earningsimp 5/10
2026-08-10 (est.)Phase 3 · Ruxolitinib Creamimp 9/10
2026-09-28 (est.)Phase 2 · INCB099280imp 7/10
2026-10-09 (est.)Phase 3 · Ruxolitinib Creamimp 9/10
2026-10-19 (est.)Phase 3 · Povorcitinibimp 9/10
2026-11-05 (est.)Phase 2 · parsaclisib + itacitinibimp 7/10
2026-12-26 (est.)Phase 3 · Povorcitinibimp 9/10

Pipeline

Asset	Phase	Indication
INCA034176	Phase 3	Chronic Graft-versus-host-disease
Povorcitinib	Phase 3	NonSegmental Vitiligo
Ruxolitinib Cream	Phase 3	Nonsegmental Vitiligo With Genital Involvement
INCB001158	Phase 2	Biliary Tract Cancer (BTC)
Pemetrexed	Phase 3	Metastatic Squamous Non-Small Cell Lung Cancer
INCB177054	Phase 2	Solid Tumors
ICS-LABA	Phase 2	Moderate to Severe Asthma
Itacitinib	Phase 3	MPN (Myeloproliferative Neoplasms)
pembrolizumab + epacadostat	Phase 3	Melanoma
Pemigatinib	Phase 2	Non-Small Cell Lung Cancer (NSCLC)
Extracorporeal photopheresis (ECP)	Phase 3	Graft-versus-host Disease (GVHD)
Ruxolitinib 25 mg	Phase 2	Multiple Myeloma
Nivolumab	Phase 2	B-cell Malignancies
Asparaginase Erwinia Chrysanthemi	Phase 2	Leukemia
ruxolitinib tablets	Phase 3	Polycythemia Vera
INCB013739	Phase 2	Type 2 Diabetes
INCB000928	Phase 2	Anemia
Ruxolitinib phosphate cream	Phase 2	Psoriasis
INCB054707	Phase 2	Hidradenitis Suppurativa
Parsaclisib	Phase 2	B-Cell Malignancies

Price & technical context

3-month

+20.9%

6-month

+14.6%

12-month

+67.0%

52-wk range

$67.27–$114.66

vs 50-day MA

+13.5%

vs 200-day MA

+16.3%

Realized vol

34.2%

Max drawdown

-33.8%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for INCY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.